Staging of Alzheimer’s disease: past, present, and future perspectives.
Therriault J, Zimmer ER, Benedet AL, Pascoal TA, Gauthier S, Rosa-Neto P.
Trends Mol Med. 2022 Sep;28(9):726-741. doi: 10.1016/j.molmed.2022.05.008. Epub 2022 Jun 15.
Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer’s disease.
Therriault J, Pascoal TA, Savard M, Mathotaarachchi S, Benedet AL, Chamoun M, Tissot C, Lussier FZ, Rahmouni N, Stevenson J, Qureshi MNI, Kang MS, Thomas É, Vitali P, Soucy JP, Massarweh G, Saha-Chaudhuri P, Gauthier S, Rosa-Neto P.
Sci Transl Med. 2022 Aug 24;14(659):eabc8693. doi: 10.1126/scitranslmed.abc8693. Epub 2022 Aug 24.
Comment on “Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases”.
Zimmer ER, Pascoal TA, Rosa-Neto P, Nordberg A, Pellerin L.
Sci Transl Med. 2022 Aug 24;14(659):eabm8302. doi: 10.1126/scitranslmed.abm8302. Epub 2022 Aug 24.
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease.
Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, Brum WS, Benedet AL, Ashton NJ, De Bastiani MA, Rocha A, Therriault J, Lussier FZ, Chamoun M, Servaes S, Bezgin G, Kang MS, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Klunk WE, Tudorascu DL, Cohen AD, Villemagne VL, Gauthier S, Blennow K, Zetterberg H, Souza DO, Karikari TK, Zimmer ER, Rosa-Neto P, Pascoal TA.
Mol Psychiatry. 2022 Aug 10. doi: 10.1038/s41380-022-01716-2. Online ahead of print.
[11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease.
Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, Kang MS, Mathotaarachchi S, Benedet AL, Therriault J, Lussier FZ, Schroeder FA, DuBois JM, Hightower BG, Gilbert TM, Zürcher NR, Wang C, Hopewell R, Chakravarty M, Savard M, Thomas E, Mohaddes S, Farzin S, Salaciak A, Tullo S, Cuello AC, Soucy JP, Massarweh G, Hwang H, Kobayashi E, Hyman BT, Dickerson BC, Guiot MC, Szyf M, Gauthier S, Hooker JM, Rosa-Neto P.
Nat Commun. 2022 Jul 19;13(1):4171. doi: 10.1038/s41467-022-30653-5.
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.
Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, Lantero-Rodriguez J, Pascoal TA, Suárez-Calvet M, Rosa-Neto P, Blennow K, Zetterberg H.
Nat Rev Neurol. 2022 Jul;18(7):400-418. doi: 10.1038/s41582-022-00665-2. Epub 2022 May 18.
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease.
Nilsson J, Ashton NJ, Benedet AL, Montoliu-Gaya L, Gobom J, Pascoal TA, Chamoun M, Portelius E, Jeromin A, Mendes M, Zetterberg H, Rosa-Neto P, Brinkmalm A, Blennow K.
Alzheimers Res Ther. 2022 Jun 4;14(1):78. doi: 10.1186/s13195-022-01021-8.
18F-MK-6240 tau-PET in genetic frontotemporal dementia.
Levy JP, Bezgin G, Savard M, Pascoal TA, Finger E, Laforce R, Sonnen JA, Soucy JP, Gauthier S, Rosa-Neto P, Ducharme S.
Brain. 2022 Jun 3;145(5):1763-1772. doi: 10.1093/brain/awab392.
Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic.
Kang MS, Shin M, Ottoy J, Aliaga AA, Mathotaarachchi S, Quispialaya K, Pascoal TA, Collins DL, Chakravarty MM, Mathieu A, Sandelius Å, Blennow K, Zetterberg H, Massarweh G, Soucy JP, Cuello AC, Gauthier S, Waterston M, Yoganathan N, Lessard E, Haqqani A, Rennie K, Stanimirovic D, Chakravarthy B, Rosa-Neto P.
J Cereb Blood Flow Metab. 2022 May;42(5):788-801. doi: 10.1177/0271678X211035625. Epub 2021 Aug 11.